Lilly began research in New Mexico on coVID-19 and the antibody bamlanivimab (LY-CoV555).

Lilly announced today that it has begun research on COVID-19 and antibody bamlanivimab (LY-CoV555) in collaboration with local agencies in New Mexico.
study in New Mexico will allow data on the effectiveness and safety of bamlanivimab to be collected in the real world.
Bamlanivimab was recently granted emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of patients with mild to moderate COVID-19 and/or COVID-19 hospitalizations.
, chief scientific officer at Lilly, said: "It is important to build the evidence base for bamlanivimab.
addition to collecting efficacy and safety data, Lilly will use the study to explore the use of bamlanivimab in a variety of environments, which may help guide best practices."
study will begin in the coming weeks and will assess the effectiveness of bamlanivimab in reducing COVID-19 hospitalizations in high-risk populations.
the study, New Mexico will use a variety of infusion techniques to enable patients in different communities to use bamlanivimab, including the Amerindian community.
。